Professor Robert S. Langer, Sc.D. (Massachusetts Institute of Technology) was awarded the prestigious 2017 Kabiller Prize in Nanoscience and Nanomedicine for 2017, from Northwestern University. The Kabiller Prize is one of the largest monetary award ($250,000) in the world founded by Northwestern trustee and alumnus David G. Kabiller to distinguish outstanding researchers in the field of nanotechnology for biomedical application. Professor Langer has the highest citation number in history and holds 1284 issued and pending patents. He was honored for his strong leadership and interdisciplinary research in developing novel nanocarriers for delivering small molecule drugs.
Professor Ali Khademhosseini, Ph.D. (University of California, Los Angeles) was honored with the 2018 Acta Biomaterialia Silver Medal. He was recognized as a leader in developing interdisciplinary research for biomaterials science, including the development of micro-and nanoscale biomaterials and engineering approaches for controlling cellular behavior for tissue engineering. Professor Khademhosseini will receive his award at the 2018 Meeting of the Society for Biomaterials in Atlanta, Georgia.
Professor Award has recognized progress in both the clinical research and basic science related to breast cancer. Professor Slamon is being recognized for his significant contributions in basic science and clinical research in identifying the breast cancerrelated gene and the development of targeted therapies, which were approved by the Food and Drug Administration and saved many lives.
Academy and Society Inductions
The National Academy of Medicine (NAM) announced 70 new regular members and 10 international members during its 2017 annual meeting. NAM members are elected based on their outstanding research achievements and public service commitment related to the fields of health and medicine. NAM was established by the National Academy of Sciences in 1970 to address critical issues in health, medicine, science, and relate policy. 
University Positions
Professor J. Brooks Jackson, M.D., was appointed as vice president for medical affairs and dean of the Roy J. and Lucille A. Carver College of Medicine, at the University of Iowa. He was the principal investigator of the National Institutes of Health-funded AIDS researches, developing effective clinical prevention and treatment of pediatric HIV infections and complications. Since 2014, he has served as the dean of the medical school and the vice president for health sciences at the University of Minnesota.
Professor Charles M. Lieber was named the first Joshua and Beth Friedman University Professor, which is the highest faculty rank in Harvard University. He is a pioneer in nanotechnology field and made numerous advances in nanoscale medicine, neurobiology, electronics, and nanocomputing, improving the quality of patients. He created an injectable nanoelectrical implant that enables the interface of the implant to act like sensors in the brain. This Professorship was established by Joshua S. Friedman and Beth C. Friedman, who are a co-founder of hedge fund Canyon Partners and a philanthropist, respectively.
Views: Recent Advances in the Field

Advancements in Industry
Asterias Biotherapeutics, a biotechnology company, reported that a new cell therapy could improve the recovery of the patients who had paralyzing spinal cord injuries and lost motor function below the injury location. Ten million of oligodendrocyte progenitor cells (AST-OPC1) which were derived from the human embryonic stem cells were injected into each patient to support nerve cell function in a damaged spinal cord. The improvements in patients who received the cell therapy were continued after 12 months and the recovery rate was increased to 67%, which was more than double times compared to previous approaches. This study was partly supported by a $1.43 million grant from the California Institute for Regenerative Medicine.
According to Informa Pharma Intelligence, the world's leading provider of strategic analysis for pharmaceutic, medical technology, and clinical research in the markets, announced that regenerative medicine market is currently valued at $68 billion and continuously growing. This growth of the market is driven by a federal government and market interest, including Johnson & Johnson, AstraZeneca, and Celgene. In particular, cellular products and gene editing market are rapidly expanding due to CRISPR-Cas9 tools. 
Advancements in Academia
Views: Government and Public Policy
The Food and Drug Administration (FDA) approved CAR-T cell therapy called Yescarta, which is a revolutionary cellular therapy for oncology that genetically modifies the autologous immune cells to directly attack cancer. FDA Commissioner Scott Gottlieb, M.D., announced that FDA will also soon establish a comprehensive policy to efficiently support other safe and effective cell-based regenerative medicines.
